<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Endra Life Sciences Inc — News on 6ix</title>
    <link>https://6ix.com/company/endra-life-sciences-inc</link>
    <description>Latest news and press releases for Endra Life Sciences Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/endra-life-sciences-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a12778dffbe2df1092e0.webp</url>
      <title>Endra Life Sciences Inc</title>
      <link>https://6ix.com/company/endra-life-sciences-inc</link>
    </image>
    <item>
      <title>ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-2</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-2</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for</description>
    </item>
    <item>
      <title>ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-taeus-liver-matches-mri-130000967</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-taeus-liver-matches-mri-130000967</guid>
      <pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., December 04, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (&quot;ENDRA&quot; or the &quot;Company&quot;), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS’ thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.</description>
    </item>
    <item>
      <title>ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-feasibility-study-demonstrates-taeus-130000420</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-feasibility-study-demonstrates-taeus-130000420</guid>
      <pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., November 20, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (&quot;ENDRA&quot; or the &quot;Company&quot;), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease (&quot;MASLD&quot;) and metabolic dysfunction-associated steatohepatitis (&quot;MASH&quot;), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key b</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-recaps-major-130000427</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-recaps-major-130000427</guid>
      <pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., November 17, 2025--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (&quot;ENDRA&quot; or the &quot;Company&quot;), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (&quot;MASLD&quot;) and metabolic dysfunction associated steatohepatitis (&quot;MASH&quot;), today provided a business update and reported financial results for the three and nine months ended September 30, 2025.</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-commences-staking-of-hype-digital-asset-holdings-reinforcing-long-term-strategy-with-anchorage-digital-and-arca</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-commences-staking-of-hype-digital-asset-holdings-reinforcing-long-term-strategy-with-anchorage-digital-and-arca</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>ENDRA is converting static treasury assets into a dynamic rewards engine to support medical innovation ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-at-market-private-placement-of-up-to-dollar144-million-to-launch-digital-asset-treasury-strategy-managed-by-leading-crypto-asset-manager-arca</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-at-market-private-placement-of-up-to-dollar144-million-to-launch-digital-asset-treasury-strategy-managed-by-leading-crypto-asset-manager-arca</guid>
      <pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
      <description>Company Also Intends to Appoint Jeff Dorman to Digital Asset Advisory Board ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (Nasdaq: NDRA)</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-provides-business-200500968</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-provides-business-200500968</guid>
      <pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., August 14, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025.</description>
    </item>
    <item>
      <title>ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-ongoing-multisite-pilot-study-120000318</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-ongoing-multisite-pilot-study-120000318</guid>
      <pubDate>Mon, 16 Jun 2025 12:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., June 16, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device’s probe design and proprietary algorithms, measu</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-provides-business-200500242</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-provides-business-200500242</guid>
      <pubDate>Thu, 15 May 2025 20:05:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., May 15, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025.</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-enhanced-120500159</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-enhanced-120500159</guid>
      <pubDate>Mon, 31 Mar 2025 12:05:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., March 31, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies.</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-fourth-120000665</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-fourth-120000665</guid>
      <pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich., March 31, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update.</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-third-quarter-2024-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-third-quarter-2024-financial-results-and-provides-a-business-update</guid>
      <pubDate>Fri, 15 Nov 2024 05:00:00 GMT</pubDate>
      <description>Company accelerated enrollment in global multisite pilot study and significantly reduced operating expenses while refocusing resources to clinical and</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-further-strengthens-taeusr-platform-intellectual-property-with-issuance-of-17th-european-patent</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-further-strengthens-taeusr-platform-intellectual-property-with-issuance-of-17th-european-patent</guid>
      <pubDate>Wed, 06 Nov 2024 05:00:00 GMT</pubDate>
      <description>Global Intellectual Property Portfolio Now Includes 82 Issued Patents ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-activates-taeus-system-to-initiate-clinical-study-at-lmu-university-hospital-in-germany</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-activates-taeus-system-to-initiate-clinical-study-at-lmu-university-hospital-in-germany</guid>
      <pubDate>Tue, 22 Oct 2024 04:00:00 GMT</pubDate>
      <description>Scans first patient in post-CE mark clinical study with Munich’s center of excellence in Europe’s largest healthcare market ANN ARBOR, Mich.--(BUSINESS</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-second-quarter-2024-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-second-quarter-2024-financial-results-and-provides-a-business-update</guid>
      <pubDate>Thu, 22 Aug 2024 04:00:00 GMT</pubDate>
      <description>Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-reverse-stock-split</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-reverse-stock-split</guid>
      <pubDate>Fri, 16 Aug 2024 04:00:00 GMT</pubDate>
      <description>Shares Expected to Begin Trading on Split-Adjusted Basis on August 20, 2024 ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reschedules-second-quarter-conference-call-to-august-22-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reschedules-second-quarter-conference-call-to-august-22-2024</guid>
      <pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Announces Leadership Changes</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-leadership-changes</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-leadership-changes</guid>
      <pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
      <description>Board Member Alexander Tokman appointed as acting CEO bringing 24+ years of global commercial leadership experience Two additional industry veterans join in</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-pricing-of-dollar80-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-announces-pricing-of-dollar80-million-public-offering</guid>
      <pubDate>Tue, 04 Jun 2024 04:00:00 GMT</pubDate>
      <description>ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound</description>
    </item>
    <item>
      <title>ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-first-quarter-2024-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/endra-life-sciences-inc/news/endra-life-sciences-reports-first-quarter-2024-financial-results-and-provides-a-business-update</guid>
      <pubDate>Tue, 14 May 2024 04:00:00 GMT</pubDate>
      <description>Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo</description>
    </item>
  </channel>
</rss>